title: [Efficacy, tolerance and acceptability of Incontex in spayed bitches with urinary incontinence].
abstract: A clinical study about efficacy and acceptance of Incontex in spayed bitches with urinary incontinence was performed. In a randomised, double-blinded study the efficacy and acceptance of Incontex (Dr. E. Gräub AG, Bern, Schweiz) in bitches with urethral sphincter incompetence due to spaying was evaluated under field conditions. The active ingredient of the Incontex Syrup is phenylpropanolamine (PPA), an alpha1-adrenergic agonist. The study was performed using 24 spayed, incontinent bitches. Over a first period of treatment of 30 days the bitches received either Incontex, at 1.5 mg/kg twice per day, or a placebo. In the second period of 30 days all 24 bitches were treated with Incontex at the recommended dose. Any changes in the incontinence compared with the situation before the study were evaluated.
  
  
  RESULTS
  Of 24 bitches 21 (88%) became continent and in 2 bitches (8%) urinary incontinence improved. In only 1 bitch (4%) the medication did have no effect. Five bitches (21%) showed side effects. The acceptance of Incontex was good.
  
  
  CONCLUSIONS
  Incontex can be recommended as an efficient and well-tolerated medication for the treatment of bitches with urinary incontinence after spaying. The oral application of 1.5mg/kg BW phenylpropanolamine twice daily has been approved.
authors: Klinik für Fortpflanzungsmedizin der Universität Zürich.
authors: T
authors: T
authors: Burgherr
authors: I
authors: I
authors: Reichler
authors: L
authors: L
authors: Hung
authors: M
authors: M
authors: Hubler
authors: S
authors: S
authors: Arnold
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000209:etiology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D010052:Ovariectomy / Q000009:adverse effects / Q000662:veterinary*; D010665:Phenylpropanolamine / Q000009:adverse effects / Q000627:therapeutic use*; D012449:Safety; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*
chemical_list: D000316:Adrenergic alpha-Agonists; D010665:Phenylpropanolamine